Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
12 pending office actions • 9 art units • 11 examiners • 0 of 12 (0%) have an AI response strategy ready • 14 patents granted in the last 365 days
Miltenyi Biotec B.V. & Co. KG currently faces 13 pending office actions within the Biotechnology & Pharmaceuticals technology area. These actions are handled by 12 distinct examiners, indicating a broad distribution of the portfolio across the USPTO's examining corps. This high number of examiners suggests a diversified prosecution strategy where individual examiner tendencies are less likely to impact the entire portfolio.
The prosecution is spread across 10 distinct art units, which demonstrates significant technical diversity in the company's pending applications. GAO, ASHLEY HARTMAN is the busiest examiner for this portfolio, managing 2 pending office actions. This indicates that even the most active examiner for the company holds a relatively small portion of the total 13 pending office actions.
The ratio of 13 pending office actions to 12 distinct examiners suggests that almost every active case is being reviewed by a unique examiner. This high number of 10 distinct art units implies that the Biotechnology & Pharmaceuticals work covers a wide array of specific sub-disciplines. For practitioners, this means that prosecution success depends on navigating many different examiner styles and art unit cultures simultaneously.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 2 (17%) |
| §112 only | 3 (25%) |
| Double-patenting + other | 1 (8%) |
| Multi-statute (no §101) | 6 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| GAO, ASHLEY HARTMAN | 2 | 56.7% | +38.2% |
| NGUYEN, THONG Q | 1 | 67.8% | +12.0% |
| RAHMAN, MASUDUR | 1 | 72.7% | +31.7% |
| KAPUSHOC, STEPHEN THOMAS | 1 | 46.5% | +53.5% |
| SCHLOOP, ALLISON ELIZABETH | 1 | 63.0% | +56.5% |
| BUNNER, BRIDGET E | 1 | 64.5% | +19.9% |
| GREENE, CAROLYN LEE | 1 | 65.3% | +47.3% |
| DU, SURBHI M | 1 | 66.9% | +29.1% |
| STAVROU, CONSTANTINA E | 1 | 43.7% | +36.9% |
| DIBRINO, MARIANNE | 1 | 42.8% | +42.2% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 6 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18024603 | CONJUGATES HAVING AN ENZYMMATICALLY RELEASABLE DETECTION MOIETY AND A BARCODE MOIETY | GAO, ASHLEY HARTMAN | 17d overdue |
| 18701572 | Method for the generation of genetically modified NK cells | RAHMAN, MASUDUR | — |
| 18572107 | UNIT-DNA COMPOSITION FOR SPATIAL BARCODING AND SEQUENCING | KAPUSHOC, STEPHEN THOMAS | — |
| 18035356 | Methods and compositions for eliminating engineered immune cells | BUNNER, BRIDGET E | — |
| 17799870 | Method for providing personalized cells with chimeric antigen receptors (CAR) against tumor microenvironment cells | STAVROU, CONSTANTINA E | — |
| 17797419 | Immune cell expressing adapter chimeric antigen receptor for sensing soluble antigens | DIBRINO, MARIANNE | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18024603 | CONJUGATES HAVING AN ENZYMMATICALLY RELEASABLE DETECTION MOIETY AND A BARCODE MOIETY | GAO, ASHLEY HARTMAN | 17d overdue |
| 18657878 | METHOD AND APPARATUS FOR HIGH RESOLUTION MICROSCOPY | NGUYEN, THONG Q | — |
| 18701572 | Method for the generation of genetically modified NK cells | RAHMAN, MASUDUR | — |
| 18572107 | UNIT-DNA COMPOSITION FOR SPATIAL BARCODING AND SEQUENCING | KAPUSHOC, STEPHEN THOMAS | — |
| 18373441 | GENE SPECIFIC TISSUE INFORMATION AND SEQUENCING | SCHLOOP, ALLISON ELIZABETH | — |
| 18369273 | BIOLOGICAL CONJUGATES HAVING AN PHOTOGENERATED ACIDIC OR BASIC RELEASABLE DETECTION MOIETY ON TOP OF BIOLOGICAL TISSUES | GAO, ASHLEY HARTMAN | — |
| 18035356 | Methods and compositions for eliminating engineered immune cells | BUNNER, BRIDGET E | — |
| 18307406 | EX-SITU SEQUENCING OF RCA PRODUCT GENERATED IN-SITU | GREENE, CAROLYN LEE | — |
| Art Unit | Apps |
|---|---|
| 1683 | 2 |
| 1678 | 2 |
| 2872 | 1 |
| 1647 | 1 |
| 1681 | 1 |
| 1765 | 1 |
| 1632 | 1 |
| 1641 | 1 |
| 1672 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18657878 | METHOD AND APPARATUS FOR HIGH RESOLUTION MICROSCOPY | NGUYEN, THONG Q | 2872 | §112 | Non-Final OA | — | Pending | May 08, 2024 |
| 18701572 | Method for the generation of genetically modified NK cells | RAHMAN, MASUDUR | — | §102§103 | Non-Final OA | — | Pending | Apr 15, 2024 |
| 18572107 | UNIT-DNA COMPOSITION FOR SPATIAL BARCODING AND SEQUENCING | KAPUSHOC, STEPHEN THOMAS | 1683 | §102§103§112 | Non-Final OA | — | Pending | Dec 19, 2023 |
| 18373441 | GENE SPECIFIC TISSUE INFORMATION AND SEQUENCING | SCHLOOP, ALLISON ELIZABETH | 1683 | §112 | Final Rejection | — | Pending | Sep 27, 2023 |
| 18369273 | BIOLOGICAL CONJUGATES HAVING AN PHOTOGENERATED ACIDIC OR BASIC RELEASABLE DETECTION MOIETY ON TOP OF BIOLOGICAL TISSUES | GAO, ASHLEY HARTMAN | 1678 | §103DP | Non-Final OA | — | Pending | Sep 18, 2023 |
| 18035356 | Methods and compositions for eliminating engineered immune cells | BUNNER, BRIDGET E | 1647 | §103§112 | Non-Final OA | — | Pending | May 04, 2023 |
| 18307406 | EX-SITU SEQUENCING OF RCA PRODUCT GENERATED IN-SITU | GREENE, CAROLYN LEE | 1681 | §112 | Final Rejection | — | Pending | Apr 26, 2023 |
| 18024603 | CONJUGATES HAVING AN ENZYMMATICALLY RELEASABLE DETECTION MOIETY AND A BARCODE MOIETY | GAO, ASHLEY HARTMAN | 1678 | §103§112Other | Non-Final OA | 17d overdue | Pending | Mar 03, 2023 |
| 18015351 | FLUORESCENT DYES COMPRISING M-CONJUGATED 1,1 -BINAPHTHYL-BASED POLYMERS | DU, SURBHI M | 1765 | §103Other | Final Rejection | — | Pending | Jan 10, 2023 |
| 17799870 | Method for providing personalized cells with chimeric antigen receptors (CAR) against tumor microenvironment cells | STAVROU, CONSTANTINA E | 1632 | §103§112Other | Non-Final OA | — | Pending | Aug 15, 2022 |
| 17797419 | Immune cell expressing adapter chimeric antigen receptor for sensing soluble antigens | DIBRINO, MARIANNE | 1641 | §102§112 | Non-Final OA | — | Pending | Aug 03, 2022 |
| 17612410 | Method for Generation of Genetically Modified T Cells | ALAM, DANYAL HASSAN | 1672 | §103 | Non-Final OA | — | Pending | Nov 18, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial